RecruitingNot ApplicableNCT05257135
A Clinico-biological Database in Cachexia in Patients With Colon Cancer
Development of a Prospective Clinico-biological Database in Cachexia in Patients With Colon Cancer
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Enrollment
150 participants
Start Date
Dec 23, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
Creation of a prospective clinico-biological database dedicated to cachexia and undernutrition in order to carry out future research projects, to improve our knowledge of colon cancer and cachexia and to optimize the therapeutic management of patients
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Age ≥ 18 years old,
- Patient treated at the Montpellier Regional Cancer Institute for colon cancer not eligible for surgery (of the primary tumor or associated metastases), whether undergoing treatment or not,
- Patient requiring treatment for colon cancer (chemotherapy, targeted therapy, etc.),
- Patient having accepted the constraints of the research and the blood samples planned for the research
- Patient affiliated to Social Protection system
- Informed consent form signed
Exclusion Criteria6
- Patient requiring surgery (for treatment of colon cancer or metastasis)
- Patient with exclusive peritoneal carcinomatosis
- Patient requiring radiotherapy
- Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons
- Pregnant and/ or breastfeeding women
- Patient cared for an emergency context
Interventions
BIOLOGICALBiological collection
\- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05257135
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT058069319 locations
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
NCT068029912 locations